Combination therapy strategies: Unlocking the next wave of innovation in IBD (Linkedin)

At Janssen, we have made major strides in the treatment of inflammatory bowel disease (IBD) in recent years, but we still have much to achieve for the many patients who either don’t respond or have lost response to therapy. In fact, an estimated 0.8 million patients living with moderate to severe ulcerative colitis (UC) or Crohn’s disease (CD) – chronic debilitating diseases that comprise IBD – are refractory or intolerant to current therapy, and only 10 percent of people with moderate to severe IBD are in clinical remission.1